Carerx Earnings Call Signals Profitable Growth Momentum

Carerx Corporation ((TSE:CRRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Carerx Corporation’s latest earnings call carried a distinctly upbeat tone, with management highlighting a firm shift from turnaround to sustained profitability. Executives pointed to steady revenue growth, expanding margins, rising cash generation and a strengthened balance sheet, while acknowledging execution and regulatory risks that could temper the pace of future expansion.

Revenue Growth Regains Momentum

Carerx reported Q4 revenue of $96.1 million, up about 4.2% from $92.2 million a year earlier, largely driven by servicing more long-term care and retirement beds. Management framed this modest top-line growth as healthy and repeatable, anchored in a stable base of facilities and incremental wins rather than one-off events.

EBITDA Expansion Signals Better Operating Leverage

Adjusted EBITDA climbed to $8.8 million in Q4 from $7.6 million a year prior, a gain of roughly 15.8% that outpaced revenue growth. The adjusted EBITDA margin improved to 9.2% from 8.2%, reflecting efficiency gains as new beds are layered onto existing infrastructure and cost initiatives continue to bite.

First Full Year of Bottom-Line Profit

For fiscal 2025, Carerx posted revenue of $370.2 million and adjusted EBITDA of $32.9 million, for an 8.9% margin. Crucially, management marked 2025 as the first full year of positive net income at $3.3 million, underscoring that the business has moved beyond turnaround mode into sustained profitability.

Quarterly Net Income Swings into the Black

In Q4, net income reached $1.0 million versus a net loss of $2.2 million in the same quarter of 2024, a notable swing fueled by higher prescription volumes and cost savings. Lower finance costs also contributed to the bottom-line improvement, reflecting both reduced leverage and more disciplined capital management.

Bed Growth Drives Scale with Limited Extra Labor

The average number of beds served rose to 92,250 in Q4 from 87,658 a year earlier, a 5.2% increase representing more than 4,500 additional beds in 2025. Management is targeting 6,000 to 8,000 net new organic beds this year, noting that the hub-and-spoke model allows many of these beds to be added with minimal incremental staffing, enhancing profitability.

Balance Sheet Deleveraging Underpins Flexibility

Net debt declined to $27.1 million at quarter end, down from $28.8 million in the prior quarter and roughly 24% lower year over year. Net debt to adjusted EBITDA improved to 0.8 times from 0.9 times, giving the company a low-leverage profile that supports both growth investments and shareholder returns.

Operating Cash Flow Supports Payouts and Debt Reduction

Cash from operations in Q4 rose to $9.6 million from $8.4 million a year ago, a 14.3% increase that shows the earnings gains are translating into cash. Management highlighted that this cash generation funded dividend payments and ongoing debt repayment, bolstering confidence in the sustainability of capital returns.

Dividend and Buybacks Enter the Toolkit

Carerx initiated a quarterly dividend, paying $1.3 million in the latest quarter, and renewed its normal course issuer bid to repurchase shares as opportunities arise. These moves come alongside guidance for annual capital expenditures of $8 million to $10 million, suggesting management sees sufficient cash capacity to invest in growth while rewarding shareholders.

Strategic Hubs and Clinical Programs Build Moat

Operationally, the company completed the transition of British Columbia’s Lower Mainland beds to a new Burnaby hub and expanded its Oakville hub in a hub-and-spoke pilot. Management emphasized clinical and government engagement wins, including hosting policymakers, delivering more than 40,000 flu shots in Q4 and publishing a pharmacist-led diabetes management study that could deepen ties with care providers.

Deferred Tax Asset Reflects Confidence in Future Profits

Carerx recognized a deferred tax asset of roughly $23 million on the balance sheet after demonstrating sustained profitability and projecting continued taxable income. This recognition allows the company to utilize past non-capital losses over time, effectively boosting future net income and reinforcing management’s confidence in growth durability.

Cash Balance Ticks Down Despite Stronger Cash Flow

The company’s cash on hand slipped to $13.9 million at December 31, 2025 from $15.5 million at the end of Q3, a decline of about 10.3%. Management suggested this reflects active capital allocation, including dividends and investment, rather than any deterioration in underlying cash generation, which continued to improve.

Regulatory and Timing Risks for New Beds

Management cautioned that onboarding new beds can take longer than expected because license transfers and reviews by competition authorities can stretch up to a year, especially for larger deals. These delays introduce execution risk to the 6,000 to 8,000 bed growth target, potentially shifting revenue contributions across quarters even if demand ultimately materializes.

Drug Pricing Uncertainty Around Semaglutide

Executives flagged uncertainty around the potential arrival of generic versions of semaglutide in Canada later this year and any resulting price shifts. While management described this as largely a pass-through item, they acknowledged that changes in wholesale pricing could still affect revenue and cost dynamics and will need close monitoring.

M&A Pipeline Still Formative

The company sees potential acquisition opportunities but stressed that current deal discussions remain in early stages, with no definitive transactions signed. As a result, external growth from mergers and acquisitions is not baked into its near-term outlook, leaving organic expansion as the primary earnings driver for now.

Exposure to Large Customer Timelines

Although there are no major contract renewals scheduled for 2026, Carerx remains exposed to the timing of large operator consolidations and regulatory reviews that influence when new beds come on stream. Management conceded that these external factors can delay expected additions, adding variability to quarterly growth even in a constructive demand environment.

Guidance Points to Scaling Profits on Bed Growth

Looking ahead, management aims for 6,000 to 8,000 net new organic beds in 2026, which they believe could push adjusted EBITDA margins into the double digits as scale benefits kick in. Plans include adding two more hub facilities within roughly 24 months, maintaining $8 million to $10 million of annual capex, continuing the quarterly dividend and opportunistic buybacks, and selectively pursuing M&A, all underpinned by low leverage of about 0.8 times net debt to adjusted EBITDA.

Carerx’s earnings call painted the picture of a pharmacy operator that has turned the profitability corner and is now focused on scaling a capital-light, hub-based model. While regulatory timing, drug pricing uncertainty and an early-stage M&A pipeline remain watch points, investors heard a story of growing beds, expanding margins and disciplined balance sheet management that supports further upside potential.